Male breast cancer: A review of the literature

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1341-1347

  Ravandi Kashani, F ^a   Hayes, T G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti neoplastic agents; Breast neoplasms; Male; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PROTEIN P53; TAMOXIFEN;

ADRENALECTOMY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER STAGING; CLINICAL TRIAL; HAIR LOSS; HOT FLUSH; HUMAN; IMPOTENCE; INSOMNIA; LYMPH NODE METASTASIS; MALE; MASTECTOMY; ORCHIECTOMY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS;

EID: 0032146278     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00028-8     Document Type: Review

References (136)

1. 1. Landis SH, Murray T, Bolden S, et al. Cancer statistics 1998. CA Cancer J Clin 1998, 48, 6-29.
2. 2. American Cancer Society. Cancer, Facts and Figures - 1991. Atlanta, American Cancer Society, 1991, 5.
3. 3. Breasted JH. The Edwin Smith Surgical Papyrus. Chicago, University of Chicago Press, 1930, 403-406.
4. 4. Ewertz M. Epidemiology of breast cancer: the Nordic contribution. Eur J Surg 1996, 162, 97-99.
5. 5. Devesa SS, Blot WJ, Stone BJ, et al. Recent cancer trends in the United States. J Natl Cancer Inst 1995, 87, 175-182.
6. 6. Coleman MP, Estère J, Damiecki P, et al. Trends in Cancer Incidence and Mortality, IARC Scientific Publication No. 121. Lyon, WHO International Agency for Research on Cancer, 1993, 411-432.
7. 7. Ewertz M, Holmberg L, Karjalainen S, et al. Incidence of male breast cancer in Scandinavia, 1943-1982. Int J Cancer 1989, 43, 27-31.
8. 8. La Vecchia C, Levi F, Lucchini F. Descriptive epidemiology of male breast cancer in Europe. Int J Cancer 1992, 51, 62-66.
9. 9. Horm JW, Asire AJ, Young JL, et al. (eds). SEER Program: Cancer Incidence and Mortality in the United States 1973-1981. NIH Publication No. 85-1837. Bethesda, Maryland, U.S. Department of Health and Human Services, 1984, 54-55.
10. 10. Crichlow RW. Carcinoma of the male breast. Surg Gynecol Obstet 1972, 13, 1011-1019.
11. 11. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 1984, 2, 903-909.
12. 12. Ribeiro G. Male breast carcinoma - a review of 301 cases from the Christie Hospital and Holt Radium Institute, Manchester. Br J Cancer 1985, 51, 115-119.
13. 13. Schotterfield D, Lilienfeld AM. Some epidemiologic features of breast cancer among males. Am J Public Health 1963, 53, 890-897.
14. 14. Sandler B, Carman C, Perry RR. Cancer of the male breast. Am Surg 1994, 60, 816-820.
15. 15. El-Gazayerli MM, Abdel-Aziz AS. On bilharziasis and male breast cancer in Egypt. Br J Cancer 1963, 17, 556-571.
16. 16. Amir H, Makwaya CK, Moshiro C, et al. Carcinoma of the male breast: a sexually transmitted disease? East Afr Med J 1996, 73, 187-189.
17. 17. Bhagwandin SS. Carcinoma of the male breast in Zambia. East Afr Med J 1972, 49, 176-179.
18. 18. Wagner JL, Thomas CR Jr, Koh WJ, et al. Carcinoma of the male breast: update 1994 [clinical conference]. Med Ped Oncol 1995, 24(2), 123-132.
19. 19. Cutuli BF, Velten M, Florentz P, et al. Cancer du sein chez l'homme: 106 observations. Presse Medicale 1993, 22, 463-466.
20. 20. Sasco AJ, Lowenfels AB, Pasker-De Jonc P. Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected etiologic factors. Int J Cancer 1993, 53, 538-549.
21. 21. Thomas DB, Jimenez LM, McTiernan A, et al. Breast cancer in men: risk factors with hormonal implications. Am J Epid 1992, 135, 734-748.
22. 22. Misra SP, Misra V, Dwivedi M. Cancer of the breast in a male cirrhotic: is there an association between the two? Am J Gastro 1996, 91(2), 380-382.
23. 23. Symmers WS. Carcinoma of the breast in transsexual individuals after surgical and hormonal interference with the primary and secondary sexual characteristics. Br Med J 1968, 2, 83-87.
24. 24. Pritchard TJ, Pankowsky DA, Crowe JP, et al. Breast cancer in male-to-female transsexual: a case report. J Am Med Assoc 1988, 259, 2278-2280.
25. 25. O'Grady WP, McPivin RW. Breast cancer in a man treated with diethylstilbestrol. Arch Path 1969, 88, 162-165.
26. 26. Schlappack OK, Braun O, Maier U. Report of 2 cases of male breast cancer after prolonged estrogen treatment for prostatic carcinoma. Cancer Detect Prev 1986, 9, 319-322.
27. 27. Calabresi E, DeGuil G, Becciolione A, et al. Plasma estrogens and androgens in male breast cancer. J Steroid Biochem 1976, 7, 605-609.
28. 28. Ballerini P, Recchione C, Cavalleri A, et al. Hormones in male breast cancer. Tumori 1990, 76, 26-28.
29. 29. Mabuchi K, Bross DS, Kessler II. Risk factors in male breast cancer. J Natl Cancer Inst 1985, 74, 371-375.
30. 30. Cohen R, Schauer PK. Male breast cancer following repeated fluoroscopy. Am J Med 1984, 76, 929-930.
31. 31. Demers PA, Thomas DB, Rosenblatt KA, et al. Occupational exposure to electromagnetic fields and breast cancer in men. Am J Epidemiol 1991, 134, 340-347.
32. 32. Matanoski GM, Breysse PN, Elliot EA. Electromagnetic field exposure and breast cancer. Lancet 1991, 337(8743), 737.
33. 33. Olsson H, Ranstam J. Head trauma and exposure to prolactin elevating drugs as risk factors for male breast cancer. J Natl Cancer Inst 1988, 80, 679-683.
34. 34. Raviglione MC, Graham PE. Breast carcinoma in a man following local trauma. NY State J Med 1987, 87, 186-187.
35. 35. Demeter JG, Waterman NG, Verdi GD. Familial male breast carcinoma. Cancer 1990, 65, 2342-2343.
36. 36. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q 12-13. Science 1994, 265, 2088-2090.
37. 37. Thorlacius S, Tryggvadottir L, Olafsdottir GH, et al. Linkage to BRCA2 region in hereditary male breast cancer. Lancet 1995, 346, 544-545.
38. 38. Stratton MR, Ford D, Neuhausen S, et al. Familial male breast cancer is not linked to the BCRA1 locus on chromosome 17q. Nature Genetics 1994, 7, 103-107.
39. 39. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992, 84, 1114-1117.
40. 40. Casagrande JT, Hanisch R, Pike MC, et al. A case-control study of male breast cancer. Cancer Res 1988, 48, 1326-1330.
41. 41. Kessler LRS II. Selected aspects of breast cancer etiology and epidemiology. Proc Am Assoc Cancer Res 1980, 21, 72.
42. 42. Moore MP. Male breast cancer. In Harris JR, Lippman ME, Morrow M, et al., eds. Diseases of the Breast. New York, Lippincott-Raven, 1996, 859-863.
43. 43. Harris J, Morrow M, Norton L. Malignant tumors of the breast. In De Vita VT Jr, et al., eds. Cancer: Principles and Practice of Oncology, 5th edition. Philadelphia, Lippincott-Raven, 1997, 1557-1616.
44. 44. Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer: a review of 104 cases. Ann Surg 1992, 215, 451-459.
45. 45. Scheike O. Male breast cancer; clinical manifestations in 257 cases in Denmark. Br J Cancer 1973, 28, 552-562.
46. 46. Treves N, Robbins FG, Amorosos WL. Serous and serosanguineous discharge from the male nipple. Arch Surg 1956, 73, 310.
47. 47. Crichlow RW, Kaplan EL, Kearney WH. Male mammary cancer. An analysis of 32 cases. Ann Surg 1972, 175, 489-494.
48. 48. Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males: a report of 335 cases. Cancer 1993, 71, 154-161.
49. 49. Lartigua E, El-jabbour JV, Dubray B, et al. Male breast carcinoma: a single center report of clinical parameters. Clin Oncol 1994, 6, 162-166.
50. 50. Donegan WL, Perez-Mesa CM. Carcinoma of male breast: a 30-year review of 28 cases. Arch Surg 1973, 106, 273-279.
51. 51. Hodson GR, Urdaneta LF, Al-Jurf AS, et al. Male breast carcinoma. Am Surg 1985, 51, 47-49.
52. 52. Hultborn R, Friberg S, Hultborn KA. Male breast carcinoma. A study of the total material reported to the Swedish Cancer Registry 1958-1967 with respect to clinical and histopathologic parameters. Acta Oncol 1987, 26, 241-256.
53. 53. Digenis AG, Ross CB, Morrison JG, et al. Carcinoma of the male breast: a review of 41 cases. South Med J 1990, 83, 1162-1167.
54. 54. Salvadori B, Saccozzi R, Manzari A, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994, 30A, 930-935.
55. 55. Detraux P, Benmussa M, Tristant H, et al. Breast disease in the male: galactographic evaluation. Radiology 1983, 154, 605-606.
56. 56. Jackson VP, Gilmor RL. Male breast carcinoma and gynecomastia: comparison of mammography with sonography. Radiology 1983, 149, 533-536.
57. 57. Bhagat P, Kline TS. The male breast and malignant neoplasms: diagnosis by aspiration biopsy cytology. Cancer 1990, 65, 2338-2341.
58. 58. Sneige N, Holder PD, Katz RL, et al. Fine needle aspiration cytology of the male breast in a cancer center. Diag Cytopathol 1993, 9, 691-697.
59. 59. Mottolese M, Bigotti G, Coli A, et al. Potential use of monoclonal antibodies in the diagnostic distinction of gynecomastia from breast carcinoma in men. Am J Clin Pathol 1991, 96, 233-237.
60. 60. Jonasson JG, Agnarsson BA, Thorlacius S, et al. Male breast cancer in Iceland. Int J Cancer 1996, 65(4), 446-449.
61. 61. Cutuli B, Dilhuydy JM, De Lafontan B, et al. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer 1997, 33, 35-38.
62. 62. Sanchez AG, Villanueva AG, Redondo C. Lobular carcinoma of the breast in a patient with Klinefelter's syndrome. A case with bilateral synchronous, histologically different breast tumors. Cancer 1986, 57, 1181-1183.
63. 63. Nance KV, Reddick RL. In situ and infiltrating lobular carcinoma of the male breast. Hum Pathol 1989, 20, 1220-1222.
64. 64. Sina B, Samorodin CS. Bilateral inflammatory carcinoma of the male breast. Cutis 1984, 33, 501-502.
65. 65. Visfeldt J, Scheike O. Male breast cancer. Histologic typing and grading of 187 Danish cases. Cancer 1973, 32, 985-990.
66. 66. Joshi MG, Lee AKC, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996, 77, 490-498.
67. 67. Jimenez-Ayala M, Diez-Nau MD, Larrad A, et al. Hemangiopericytoma in a male breast. Report of a case with cytologic, histologic and immunologic studies. Acta Cytol 1991, 35, 234-238.
68. 68. Spatz MW. Breast cancer in men. Am Fam Phys 1988, 38, 187-189.
69. 69. Allen FJ, Van Velden DJ. Prostate carcinoma metastatic to male breast. Br J Urol 1991, 67, 424-435.
70. 70. Verger E, Conil C, Velasco M, et al. Metastasis in the male breast from a lung adenocarcinoma. Acta Oncol 1992, 31, 479.
71. 71. Stebbings WSL, George BD, Boyle S, et al. Malignant cysts of the male breast. Postgrad Med J 1987, 63, 985-987.
72. 72. Bezwoda WR, Hesdorffer C, Dansey R, et al. Breast cancer in men: clinical features, hormone receptor status and response to therapy. Cancer 1987, 60, 1337-1340.
73. 73. Gupta N, Cohen JL, Rosenbaum C, et al. Estrogen receptors in male breast cancer. Cancer 1980, 46, 1781-1784.
74. 74. Fox SB, Rogers S, Day CA, et al. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol 1992, 166, 13-18.
75. 75. Friedman MA, Hoffman PG, Dandolos EM, et al. Estrogen receptors in male breast cancer: clinical and pathologic correlation. Cancer 1981, 47, 134-137.
76. 76. Chung HC, Kim DL, Koh EH, et al. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining in male breast cancer. Yonsei Med J 1991, 32, 126-130.
77. 77. Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995, 31A(12), 1960-1964.
78. 78. Everson RB, Lippman ME, Thompson EB, et al. Clinical correlations of steroid receptors and male breast cancer. Cancer Res 1980, 40, 991-997.
79. 79. Gattuso P, Reddy VB, Green L, et al. Prognostic significance of DNA ploidy in male breast cancer: a retrospective analysis of 32 cases. Cancer 1992, 70, 777-780.
80. 80. Cunha F, Andre S, Soares J. Morphology of male breast carcinoma in the evaluation of prognosis. Path Res Pract 1990, 186, 745-750.
81. 81. Hatschek T, Wingren S, Carstensen J, et al. DNA content and S-phase fraction in male breast carcinomas. Acta Oncol 1994, 33(6), 609-613.
82. 82. Rodgers CS, Hill SM, Hulten MA. Cytogenetic analysis in a case of cancer of the male breast. Cancer Genet Cytogenet 1985, 151, 113-117.
83. 83. Mitchell EL. A cytogenetic study of male breast cancer. Cancer Genet Cytogenet 1990, 47, 107-112.
84. 84. Balazs M, Mayall BH, Waldman FM. Interphase cytogenetics of a male breast cancer. Cancer Genet Cytogenet 1991, 55, 243-247.
85. 85. Donegan WL, Redlich PN. Breast cancer in men. Surg Clin North America 1996, 76, 343-363.
86. 86. Yap HY, Tashima CK, Blumenschein GR, et al. Male breast cancer. A natural history study. Cancer 1979, 44, 748-754.
87. 87. Winchester DJ, Goldschmidt RA, Khan SJ, et al. Flow cytometric analysis and molecular prognostic markers in male breast carcinoma patients. 46th Annual Cancer Symposium of the Society of Surgical Oncology, Los Angeles, 18-21 March 1993.
88. 88. Lee AKC, Wiley B, Loda M, et al. DNA ploidy, proliferation and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol 1992, 5, 61-67.
89. 89. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol 1992, 5(6), 621-625.
90. 90. Fox SB, Day CA, Rogers S. Lack of c-erb-2 oncoprotein expression in male breast carcinoma. J Clin Pathol 1991, 44, 960-961.
91. 91. Hollstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancers. Science 1991, 253, 49-53.
92. 92. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992, 89, 7262-7266.
93. 93. Cattoretti G, Rilke F, Andreola S, et al. P53 expression in breast cancer. Int J Cancer 1988, 41, 178-183.
94. 94. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node negative breast carcinoma: preliminary studies support cautious optimism (editorial). J Natl Cancer Inst 1993, 85, 176-177.
95. 95. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992, 84, 845-855.
96. 96. Ouriel K, Lotze MT, Hinshaw JR. Prognostic factors of carcinoma of the male breast. Surg Gynecol Obstet 1984, 159, 373-376.
97. 97. Scheike O. Male breast cancer. Factors influencing prognosis. Br J Cancer 1974, 30, 261-271.
98. 98. Spence RAJ, MacKenzie G, Anderson JR, et al. Long-term survival following cancer of the male breast in Northern Ireland. Cancer 1985, 55, 648-652.
99. 99. Chung HC, Koh EH, Roh JK, et al. Male breast cancer - a 20 year review of 16 cases at Yonsei University. Yonsei Med 1990, 31, 242-249.
100. 100. Kinne DW. Management of male breast cancer. Oncology 1991, 5, 45-47.
101. 101. Robinson R, Montague ED. Treatment results in males with breast cancer. Cancer 1982, 49, 403-406.
102. 102. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer. Br J Cancer 1992, 65, 252-254.
103. 103. Bagley CS, Wesley MN, Young RC, et al. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987, 10, 55-60.
104. 104. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989, 64, 1583-1585.
105. 105. Griffith H, Muggia FM. Male breast cancer: update on systemic therapy. Rev Endocrine-Related Cancer 1989, 31, 5-11.
106. 106. Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males: assessment of endocrine therapy. Cancer 1984, 53, 1344-1346.
107. 107. Kennedy BJ, Kiang DT. Hypophysectomy in the treatment of advanced cancer of the male breast. Cancer 1972, 29, 1606-1612.
108. 108. Crichlow RW. Breast cancer in men. Semin Oncol 1974, 1, 145-152.
109. 109. Jaiyesimi IA, Buzdar AU, Sahin AA, et al. Carcinoma of the male breast. Ann Intern Med 1992, 117, 771-777.
110. 110. Feldman LD. Ketoconazole for metastatic male breast cancer. Ann Intern Med 1986, 104, 123-124.
111. 111. Lopez M, Di Lauro L, Lazzaro B, et al. Hormonal treatment of disseminated male breast cancer. Oncology 1985, 42, 345-349.
112. 112. Lopez M. Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 1985, 55, 2334-2336.
113. 113. Vorobiof DA, Falkson G. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 1987, 59, 688-689.
114. 114. Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with LHRH analogue buserelin alone or in combination with the anti-androgen flutamide. Cancer 1988, 62, 474-478.
115. 115. Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983, 143, 237-240.
116. 116. Lopez M, Di Lauro L, Papaldo P, et al. Chemotherapy in metastatic male breast cancer. Oncology 1985, 42, 205-209.
117. 117. Izquierdo MA, Alonso C, De Andres L, et al. Male breast cancer. Report of a series of 50 cases. Acta Oncol 1994, 33, 767-771.
118. 118. Gough DB, Donohue JH, Evans MM, et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol 1993, 2, 325-333.
119. 119. Heller KS, Rosen PP, Schottenfeld D, et al. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 1978, 188, 60-65.
120. 120. Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am 1990, 70, 1165-1177.
121. 121. Langlands AO, Maclean N, Kerr GR. Carcinoma of the male breast: report of a series of 88 cases. Clin Radiol 1976, 27, 21-25.
122. 122. Slack RWT. The survival rate of men with carcinoma of the breast. Br J Surg 1975, 62, 963-965.
123. 123. Van Geel AN, van Slooten EA, Mavrunac M, et al. A retrospective study of male breast cancer in Holland. Br J Surg, 1985, 72, 724-727.
124. 124. Stalsberg H, Thomas DB, Rosenblatt KA, et al. Histologic types and hormone receptors in breast cancer in men: a population based study on 282 United States men. Cancer Causes Control 1993, 4, 143-151.
125. 125. Silfversward C, Gustafsson JA, Gustafsson SA, et al. Estrogen receptor concentrations in 269 cases of histologically classified human breast cancer. Cancer 1980, 45, 2001-2005.
126. 126. Morimoto T, Komaki K, Yamakawa T, et al. Cancer of the male breast. J Surg Oncol 1990, 44, 180-184.
127. 127. Haagensen CD. Carcinoma of the male breast, in Diseases of the breast, 3rd edition. Philadelphia, W.B. Saunders, 1986, 976-990.
128. 128. Rouvière H. Anatomie des Lymphatiques de l'Homme. Paris, Masson, 1932.
129. 129. Haagensen CD. Anatomy of the mammary glands, in Diseases of the breast, 3rd edition. Philadelphia, W.B. Saunders, 1986, 25-46.
130. 130. Turner-Warwick RT. The lymphatics of the breast. Br J Surg 1959, 46, 574-582.
131. 131. Treves N. Inflammatory carcinoma of the breast in the male patient. Surgery 1953, 34, 810-820.
132. 132. Sherry MM, Johnson DH, Page DL, et al. Inflammatory carcinoma of the breast. Clinical review and summary of the Vanderbilt experience with multi-modality therapy. Am J Med 1985, 79, 355-364.
133. 133. Fisher ER, Gregorio RM, Fisher B, et al. The pathology of invasive breast cancer. Cancer 1975, 36, 1-85.
134. 134. Lucas FV, Peres-Meza C. Inflammatory carcinoma of the breast. Cancer 1978, 41, 1595-1605.
135. 135. Cunha F, Andre S, Scares J. Morphology of male breast carcinoma in the evaluation of prognosis. Path Res Pract 1990, 186, 745-750.
136. 136. Lee AKC, DeLellis RA, Silverman ML, et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node negative carcinoma of the breast. J Clin Oncol 1990, 8, 1457-1465.